TOMI’s Newest Product, SteraBot™, Piloted at Lithuanian University Hospital to Ensure Delivery of Superior Disinfection
TOMI Environmental Solutions, Inc. (NASDAQ:TOMZ) has successfully deployed its pilot disinfection robot, SteraBot™, at the Lithuanian University Hospital of Health Sciences. This advancement aims to aid in the fight against COVID-19 and other pathogens through its cutting-edge Binary Ionization Technology (BIT) platform. Collaborating with RV Automation Technology Co. Ltd., SteraBot™ uses advanced AGV technology and AI to improve disinfection efficiency, potentially reducing costs and enhancing safety for hospital personnel and patients. The AI disinfection robot market is projected to grow at a CAGR of 28% from 2020 to 2025.
- Successful deployment of SteraBot™ at a major hospital.
- Anticipated cost savings in manpower and PPE usage.
- SteraBot™ enhances disinfection efficiency with AI technology.
- Market for AI disinfection robots expected to grow at a CAGR of 28%.
- None.
BEVERLY HILLS, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ:TOMZ), is a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist products - a hydrogen peroxide-based mist and fog composed of ionized Hydrogen Peroxide (iHP™). TOMI announces the successful deployment of SteraBot™, a pilot disinfection robot, at the Lithuanian University Hospital of Health Sciences.
In an effort to meet new standards in automation and robotics to help halt the spread of COVID-19 as well as other existing and emerging pathogens, TOMI has developed SteraBot™, a significant advancement in SteraMist disinfection technology. This first generation of SteraMist robotics technology is the result of collaboration with RV Automation Technology Co. Ltd. of Hong Kong. By utilizing extensively tested, implemented, and patented ionized Hydrogen Peroxide technology, SteraBot™ is expected to protect hospital staff, patients, and visitors. Additionally, full-time equivalent costs and personal protection equipment usage are expected to be greatly reduced.
The SteraBot™ incorporates cutting-edge Automated Guided Vehicle (AGV) technology for intuitive maneuverability in unmapped environments. The software allows for enhanced AI capability to optimize and execute mapping, autonomous navigation, and disinfection routines based on proprietary algorithms. The software also ensures the efficacy of SteraMist iHP™ disinfection under optimal operating parameters directed by TOMI.
TOMI’s continuing research and development strategy will allow for the expansion of product lines to meet the urgent requirements of customers across a wide array of global industries. Advancements in programming will ensure protocol adherence during routine disinfection cycles at any time of day and allow programmed cycles to run during optimal times in an effort to reduce facility downtimes. Further, the technology is expected to provide cost savings in manpower, providing a more efficient and effective disinfection building upon SteraMist’s established no-touch, no rinse, no wipe, and no residue disinfection.
Dr. Halden Shane, TOMI CEO, states: “SteraBot™ is an exciting breakthrough advancement for TOMI. SteraBot™ is one of many designs of TOMI disinfection robots. Stay tuned for additional robots’ models being released in the very near future. We anticipate that SteraBot™ development to be our significant first step into robotics integration that will become an invaluable asset in protecting communities within the new normal, as well as propel TOMI’s growth. The marketplace for an AI disinfection robot is maturing and TOMI should be able to take a significant share of it. The Artificial Intelligence in Robotics market is expected to register a CAGR of
Video footage of the SteraBot™ iHP™ in operation https://www.rvautotech.com/projects/disinfection-robot
TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.
TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.
TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.
For additional information, please visit http://www.tomimist.com/ or contact us at info@tomimist.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.
INVESTOR RELATIONS CONTACT
Harold Paul
hpaul@tomimist.com
FAQ
What is SteraBot™ and where was it deployed?
What technology does SteraBot™ use?
What are the expected benefits of SteraBot™?
What is the market growth forecast for AI disinfection robots?
Who collaborated with TOMI for the development of SteraBot™?
